Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis

Summary

To verify the efficacy and safety of endostatin in the treatment of SRILI（symptomatic radiation-induced lung injury） and fibrosis. The results of this study are expected to be a new clinical strategy for the treatment of radiation pneumonia and fibrosis.

Timeline

Start

2018-09-01

Primary completion

2020-05-31

Completion

2020-07-31

Outcome

Met primary endpoint

paper The relapse rate of RP was significantly lower in Rh-endostatin group (15% vs 45%, P = .038). PMID 41014160 ↗

Publications

• Chen G, Zhu J, Jian C, Chen X, Niu K, Yang Q, Tang S, Qin S, Feng Y, Xie L, Zhuo W, Sun J. Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer. Oncologist. 2025 Nov 11;30(11):oyaf318. doi: 10.1093/oncolo/oyaf318.

Drugs

Indications